BioSpace News Archive

Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a Type C meeting would be recommended, which the Company will request, to discuss the overall development plan and the latest revised endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

LeMaitre Vascular, Inc. announced that it is participating in two upcoming investor conferences.

PHISKIN, a Chinese aesthetic medicine clinics brand, has announced a new enhancement to its one-stop high-end medical service system as part of the expansion of its healthcare business

ChoiceSpine LLC, a privately-held spinal device manufacturer based in Knoxville, TN, announces the launch of an additional lordotic offering for their stand-alone anterior lumbar interbody – Harrier SA.

Alcami, a leading contract development and manufacturing organization, announced the completion of Phase II of its cGMP biostorage facility located in Amherst, New Hampshire.

CatalYm announced the close of a EUR 50 million Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion.

Oculis S.A., (Oculis) announces that the results of licaminlimab active-controlled, multicenter, randomized, parallel-group Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on anterior chamber (AC) cell grade in patients with acute anterior uveitis (AAU) (NCT02482129) has been published in Translational Vision Science &Technology (TVST), an ARVO journal.

Subtle Medical, a leading healthcare technology provider, announced it will be showcasing its award winning AI-powered software solutions, SubtleMR™ and SubtlePET™, along with a robust pipeline of new products in research and development, at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).

Alzheon, Inc. today announced that it will be presenting new clinical trial data at the 15th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference to be held from November 29 – December 2, 2022 in San Francisco, CA, USA.

Janux Therapeutics, Inc. today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings.